{"entity":{"type":"insider","cik":"0001753037","url":"/insider/0001753037","json_url":"/insider/0001753037.json","name":"5AM Ventures VI, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":11,"first":"2021-02-09","last":"2025-09-15","span_basis":"filed_date"},"name_variants":[{"name":"5AM Ventures VI, L.P.","source":"filing","n_filings":11,"first_seen":"2021-02-09","last_seen":"2025-09-15"}],"transactions":[{"id":5150256,"accession":"0001231919-25-000196","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000196","line_url":"/filing/0001231919-25-000196#line-1","is_derivative":false,"issuer_cik":"0001664281","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001664281","owner_cik":null,"owner_name":"5AM Ventures VII, L.P.; 5AM Opportunities II, L.P.; PARMAR KUSH; 5AM Opportunities II (GP), LLC; 5AM Ventures VI, L.P.; 5AM Partners VII, LLC","owner_display_name":"5AM Ventures VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2941176.0,"shares_display":"2,941,176","price_per_share":1.53,"price_display":"1.53","price_state":"stated","total_value":4499999.28,"total_display":"4,499,999.28","total_whole":"4,499,999","shares_owned_after":2941176.0,"shares_owned_after_display":"2,941,176","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-11","filed_date":"2025-09-15","scope":"insider"},{"id":3000840,"accession":"0001415889-24-025140","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-025140","line_url":"/filing/0001415889-24-025140#line-3","is_derivative":false,"issuer_cik":"0001664281","issuer_name":"Camp4 Therapeutics Corp","issuer_ticker":"CAMP","issuer_name_source":null,"issuer_url":"/issuer/0001664281","owner_cik":null,"owner_name":"PARMAR KUSH; 5AM Opportunities II (GP), LLC; 5AM Ventures VI, L.P.; 5AM Opportunities II, L.P.","owner_display_name":"PARMAR KUSH","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909090.0,"shares_display":"909,090","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":2625145.0,"shares_owned_after_display":"2,625,145","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-15","scope":"insider"},{"id":2070304,"accession":"0001415889-24-020035","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-020035","line_url":"/filing/0001415889-24-020035#line-4","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Artiva Biotherapeutics, Inc.","issuer_ticker":"ARTV","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Opportunities II (GP), LLC; PARMAR KUSH; 5AM Opportunities II, L.P.; 5AM Ventures VI, L.P.","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":833333.0,"shares_display":"833,333","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":9999996.0,"total_display":"9,999,996.00","total_whole":"9,999,996","shares_owned_after":1182054.0,"shares_owned_after_display":"1,182,054","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-07-22","filed_date":"2024-07-24","scope":"insider"},{"id":3251890,"accession":"0001415889-24-004111","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-004111","line_url":"/filing/0001415889-24-004111","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Opportunities I, L.P.; PARMAR KUSH; 5AM Ventures VI, L.P.; 5AM Opportunities I (GP), LLC","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":825000.0,"shares_display":"825,000","price_per_share":14.9,"price_display":"14.90","price_state":"stated","total_value":12292500.0,"total_display":"12,292,500.00","total_whole":"12,292,500","shares_owned_after":3200634.0,"shares_owned_after_display":"3,200,634","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-16","scope":"insider","n_lines":2},{"id":2658941,"accession":"0001415889-24-002295","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-002295","line_url":"/filing/0001415889-24-002295","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; Schwab Andrew J.; 5AM Ventures VI, L.P.; PARMAR KUSH; 5AM Opportunities I, L.P.","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","total_whole":"7,500,000","shares_owned_after":3888992.0,"shares_owned_after_display":"3,888,992","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-01-31","filed_date":"2024-02-02","scope":"insider","n_lines":2},{"id":8681058,"accession":"0001209191-23-050731","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-050731","line_url":"/filing/0001209191-23-050731","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Ventures VI, L.P.; Schwab Andrew J.; 5AM Partners VI, LLC; PARMAR KUSH; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC","owner_display_name":"5AM Ventures VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":197500.0,"shares_display":"197,500","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":2962500.0,"total_display":"2,962,500.00","total_whole":"2,962,500","shares_owned_after":4306179.0,"shares_owned_after_display":"4,306,179","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-26","filed_date":"2023-09-28","scope":"insider","n_lines":2},{"id":8043975,"accession":"0001209191-23-047514","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-047514","line_url":"/filing/0001209191-23-047514","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Ventures VI, L.P.; 5AM Partners VI, LLC; 5AM Opportunities I (GP), LLC; Schwab Andrew J.; PARMAR KUSH; 5AM Opportunities I, L.P.","owner_display_name":"5AM Ventures VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":440000.0,"shares_display":"440,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":7040000.0,"total_display":"7,040,000.00","total_whole":"7,040,000","shares_owned_after":4470968.0,"shares_owned_after_display":"4,470,968","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-24","filed_date":"2023-08-28","scope":"insider","n_lines":2},{"id":6149401,"accession":"0001209191-22-046494","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-046494","line_url":"/filing/0001209191-22-046494","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"CinCor Pharma, Inc.","issuer_ticker":"CINC","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; PARMAR KUSH; 5AM Opportunities II, L.P.; 5AM Opportunities I, L.P.; Schwab Andrew J.; 5AM Ventures VI, L.P.; 5AM Partners VI, LLC; 5AM Opportunities II (GP), LLC","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":600000.0,"shares_display":"600,000","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":18000000.0,"total_display":"18,000,000.00","total_whole":"18,000,000","shares_owned_after":487333.0,"shares_owned_after_display":"487,333","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-15","filed_date":"2022-08-17","scope":"insider","n_lines":2},{"id":6692932,"accession":"0001209191-22-003205","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-003205","line_url":"/filing/0001209191-22-003205","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"CinCor Pharma, Inc.","issuer_ticker":"CINC","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Opportunities I (GP), LLC; PARMAR KUSH; Schwab Andrew J.; 5AM Ventures VI, L.P.; 5AM Opportunities I, L.P.; 5AM Partners VI, LLC","owner_display_name":"5AM Opportunities I (GP), LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":470000.0,"shares_display":"470,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":7520000.0,"total_display":"7,520,000.00","total_whole":"7,520,000","shares_owned_after":496323.0,"shares_owned_after_display":"496,323","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-11","filed_date":"2022-01-13","scope":"insider","n_lines":2},{"id":5114310,"accession":"0001209191-21-065661","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-065661","line_url":"/filing/0001209191-21-065661","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Vor Biopharma Inc.","issuer_ticker":"VOR","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; 5AM Ventures VI, L.P.; 5AM Partners VI, LLC; Schwab Andrew J.","owner_display_name":"5AM Opportunities I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":330706.0,"shares_display":"330,706","price_per_share":15.3,"price_display":"15.30","price_state":"stated","total_value":5059801.8,"total_display":"5,059,801.80","total_whole":"5,059,802","shares_owned_after":4595089.0,"shares_owned_after_display":"4,595,089","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-11-16","filed_date":"2021-11-18","scope":"insider","n_lines":2},{"id":4882079,"accession":"0001209191-21-008925","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-008925","line_url":"/filing/0001209191-21-008925","is_derivative":false,"issuer_cik":"0001598549","issuer_name":"Vor Biopharma Inc.","issuer_ticker":"VOR","issuer_name_source":null,"issuer_url":"/issuer/0001598549","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Opportunities I, L.P.; 5AM Opportunities I (GP), LLC; 5AM Partners VI, LLC; 5AM Ventures VI, L.P.","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":555555.0,"shares_display":"555,555","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":1858470.0,"shares_owned_after_display":"1,858,470","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001736730","name":"Camp4 Therapeutics Corp","url":"/issuer/0001736730","role":"Ten percent owner","n_filings":2,"first_seen":"2024-10-15","last_seen":"2025-09-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001817241","name":"Artiva Biotherapeutics, Inc.","url":"/issuer/0001817241","role":"Ten percent owner","n_filings":1,"first_seen":"2024-07-24","last_seen":"2024-07-24"},{"type":"issuer","type_label":"ISSUER","cik":"0001672619","name":"Enliven Therapeutics, Inc.","url":"/issuer/0001672619","role":"Ten percent owner","n_filings":4,"first_seen":"2023-08-28","last_seen":"2024-02-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001868734","name":"CinCor Pharma, Inc.","url":"/issuer/0001868734","role":"Ten percent owner","n_filings":2,"first_seen":"2022-01-13","last_seen":"2022-08-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001817229","name":"Vor Biopharma Inc.","url":"/issuer/0001817229","role":"Ten percent owner","n_filings":2,"first_seen":"2021-02-09","last_seen":"2021-11-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001753037","retrieved_at":"2026-08-26T08:50:04+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}